Loading...
  • toxicity
  • 2008). Phase I/II trials showed that Laromustine had significant activity in the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic disorders, with a therapeutic ratio and toxicity profile suggesting that the drug might have value for the treatment of patients with refractory disease and in the treatment of these diseases in the aged (Giles 2007, Giles et al. (cylch.org)
  • The problems of drug access to the tumor cells, efflux, inactivation, toxicity, etc., are being addressed by advances in pharmacogenetics, delivery routes, development of new generation platinum compounds, and modifiers of metabolism and damage repair. (springer.com)
  • Moreover, current anticancer regimens are frequently associated with significant levels of toxicity and the emergence of drug resistance. (hindawi.com)
  • The process of identifying new indications for already approved drugs, called repositioning, takes advantage of existing data on toxicity, pharmacokinetics, and potential side effects. (nih.gov)
  • regimens
  • growth assays showed effects of regimens combining Laromustine and radiation that were compatible with additive or subadditive interactions. (cylch.org)
  • This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone. (clinicaltrials.gov)
  • agents
  • When the DNA in a cell becomes damaged by agents such as toxic chemicals, radiation, or ultraviolet (UV) rays from sunlight, this protein plays a critical role in determining whether the DNA will be repaired or the damaged cell will self-destruct (undergo apoptosis). (nih.gov)
  • In addition, many agents (including chemotherapeutic drugs) induce cellular stress, which may also lead to mitochondrial perturbation and, finally, cell death. (aacrjournals.org)
  • The aim of this paper is to provide an overview of the recent advances and new development of this class of drugs as potential anticancer agents. (hindawi.com)
  • Here, model hybrids were synthesized by exploring C- sp 2 chemistry ((1+2)-cycloaddition of nitrenes and amidation) of the outer MWCNT walls combined with anticancer agents, that is, 5-fluorouracil (5FU), purpurin (Purp), and 1,8-naphthalimide DNA intercalators (NIDIs), via linkers. (hindawi.com)
  • Nanomedicine exploits therapeutic and/or diagnostic (or combined "theranostic") agents as the key field of commercialization of anticancer products [ 5 ]. (hindawi.com)
  • oncologist
  • In addition, I felt much better after meeting my radiation oncologist Dr. Nancy Lee (you can watch a video interview with her under the "Videos" menu tab at the top of my blog). (mdbcancerjourney.com)
  • chemotherapeutic drugs
  • Many chemotherapeutic drugs induce mitochondrial membrane permeability transition, membrane depolarization, osmotic swelling, and release of cytochrome c , involving the opening of the permeability transition pore complex (PTPC). (aacrjournals.org)
  • effective
  • It is too early to tell whether this drug could one day be effective in the clinic, but based on our findings, it seems a question that is worth exploring. (theconversation.com)
  • survival
  • OGX-427 is a second-generation antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein. (empr.com)
  • molecular
  • The molecular structures of these two drugs share a trait that is not found in the other drugs that were tested, and the researchers speculate that this trait might provide an explanation for the relatively higher potency of these two drugs. (nih.gov)
  • cell
  • Cell type, morphology, and functioning are key variables in the construction of efficient "drug-vehicle" hybrids in magnetic drug delivery. (hindawi.com)
  • recurrent
  • It is possible that persistent disease may have a genotype and phenotype different to recurrent disease since the organ has been exposed to radiation, albeit subtherapeutic doses. (beds.ac.uk)